ACRS 10-Q: SEC filing
Aclaris Therapeutics
Filed with the SEC on · accession 0001104659-26-123374
ACRS filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. Aclaris Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial statements, equity compensation details, and segment information.
Summary of the filing
Aclaris Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial statements, equity compensation details, and segment information. No material corporate events such as executive changes, acquisitions, or guidance updates were announced.
Key details
✦ Ask GOAX AI about this filing — what it means for ACRS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ACRS?
Click hereFrequently asked questions
What did ACRS file with the SEC on Nov 5, 2026?
ACRS filed a 10-Q (SEC filing). Aclaris Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial statements, equity compensation details, and segment information. No material corporate events such as executive changes, acquisitions, or guidance updates were announced.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other ACRS SEC filings
- 424B5 · Secondary offeringOct 27, 2026
- 8-K · SEC filingOct 27, 2026
- 8-K · Fda approvalOct 27, 2026
- 8-K · SEC filingAug 6, 2026
- 10-Q · SEC filingAug 6, 2026
- 8-K · Material agreementAug 6, 2026
- 8-K · Board changeJun 4, 2026
- 8-K · SEC filingMay 7, 2026
- 10-Q · SEC filingMay 7, 2026
- 8-K · Fda approvalApr 28, 2026
Get alerts when ACRS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days